Humacyte’s (HUMA) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital restated their buy rating on shares of Humacyte (NASDAQ:HUMA) in a research report report published on Monday,Benzinga reports. The brokerage currently has a $25.00 target price on the stock.

HUMA has been the topic of a number of other research reports. Wall Street Zen lowered Humacyte from a “hold” rating to a “sell” rating in a research report on Sunday, December 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Humacyte in a report on Monday, December 29th. BTIG Research reiterated a “buy” rating and issued a $6.00 price target on shares of Humacyte in a research note on Friday, November 21st. HC Wainwright reiterated a “buy” rating and set a $3.00 price target on shares of Humacyte in a report on Monday, December 1st. Finally, UBS Group restated a “buy” rating on shares of Humacyte in a report on Monday, December 1st. Seven research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Humacyte currently has a consensus rating of “Moderate Buy” and a consensus target price of $8.29.

Humacyte Stock Performance

Shares of HUMA stock opened at $1.20 on Monday. The firm has a 50 day moving average of $1.23 and a two-hundred day moving average of $1.68. The stock has a market capitalization of $224.72 million, a PE ratio of -5.22 and a beta of 1.93. The company has a quick ratio of 0.90, a current ratio of 1.62 and a debt-to-equity ratio of 2.97. Humacyte has a 52 week low of $0.91 and a 52 week high of $4.85.

Humacyte (NASDAQ:HUMA) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.03. The company had revenue of $0.75 million for the quarter, compared to analysts’ expectations of $0.92 million. On average, research analysts predict that Humacyte will post -1.27 EPS for the current fiscal year.

Hedge Funds Weigh In On Humacyte

A number of hedge funds and other institutional investors have recently made changes to their positions in HUMA. Lazari Capital Management Inc. purchased a new position in Humacyte in the 2nd quarter valued at $27,000. Truist Financial Corp acquired a new stake in shares of Humacyte in the 3rd quarter worth $28,000. Prudential Financial Inc. acquired a new position in shares of Humacyte during the second quarter worth about $28,000. Financial Advisors Network Inc. purchased a new position in Humacyte during the second quarter worth about $28,000. Finally, Equitable Holdings Inc. acquired a new position in Humacyte during the 3rd quarter worth approximately $29,000. Hedge funds and other institutional investors own 44.71% of the company’s stock.

About Humacyte

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.